Genmab A-S

Yahoo Finance • 5 days ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announc... Full story

Yahoo Finance • 9 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of t... Full story

Yahoo Finance • 9 days ago

Novo Nordisk nominates three new board directors, two with pharma experience

[New Nordisk] hapabapa * Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira, both of whom have pharmaceutical industry experience, for its board. * Van de Winkel co-founded Genmab (GMAB [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • 11 days ago

High Growth Tech Stocks To Watch In February 2026

As global markets navigate a landscape marked by AI disruption concerns and robust U.S. job gains, major indices like the Nasdaq Composite have experienced notable declines, reflecting broader market sentiment. Amidst this backdrop, identi... Full story

Yahoo Finance • 12 days ago

Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

This article first appeared on GuruFocus. Total Revenue Growth: Increased by 19% to $3.7 billion in 2025. Operating Profit: Expanded to $1.26 billion in 2025. Sales of Proprietary Medicines: Totaled $632 million, up 54% year over year. Ab... Full story

Yahoo Finance • 12 days ago

Genmab Announces Initiation of Share Buy-Back Program

Genmab A/S Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31, 2026... Full story

Yahoo Finance • 12 days ago

Genmab Publishes 2025 Annual Report

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and... Full story

Yahoo Finance • 13 days ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Medtronic plc (MDT [https://seekingalpha.com/symbol/MDT]) * Eagle Point Credit Company (ECC [https://seekin... Full story

Yahoo Finance • 16 days ago

Pre-Market Earnings Report for February 17, 2026 : MDT, ET, VMC, DTE, LH, LDOS, GPC, SGI, GMAB, CNH, ALLE, WSO

The following companies are expected to report earnings prior to market open on 02/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Medtronic plc (MDT)is reporting for the quarter ending January 31, 2... Full story

Yahoo Finance • 16 days ago

H.C. Wainwright Bullish on ​Genmab A/S (GMAB) on Robust Sales for DARZALEX

​Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales... Full story

Yahoo Finance • 2 months ago

Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs

(RTTNews) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as EPKINLY, petosemtamab and rinatabart sesutecan. The de... Full story

Yahoo Finance • 2 months ago

Genmab Portfolio Prioritization Update

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive l... Full story

Yahoo Finance • 2 months ago

This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%

Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth. Continue Reading... Full story

Yahoo Finance • 3 months ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; Decemb... Full story

Yahoo Finance • 3 months ago

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 202... Full story

Yahoo Finance • 3 months ago

BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appoint... Full story

Yahoo Finance • 3 months ago

Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move

Dow Jones stock Caterpillar is in a buy zone following a recent breakout move as the stock market indexes rally near record highs. Continue Reading... Full story

Yahoo Finance • 3 months ago

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Media Release COPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a t... Full story

Yahoo Finance • 3 months ago

Genmab : Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL

(RTTNews) - Genmab A/S (GMAB) announced primary results from the pivotal Phase 3 EPCORE FL-1 study, evaluating fixed-duration EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with r... Full story

Yahoo Finance • 3 months ago

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Media Release COPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2)resulted in statistically significant and clinically meaningful reduction in the... Full story